Maravai LifeSciences (MRVI)
Supplies nucleic-acid tools and biologics testing products for therapies, vaccines, diagnostics, and research.
Something off on this page? Send us feedback.
Sells TriLink nucleic-acid products and Cygnus biologics safety testing tools to biopharma, diagnostics, and research customers. The business is concentrated in North America but also serves Asia Pacific and EMEA, with demand shaped by mRNA programs, biologics manufacturing workflows, and CleanCap order cycles.
Operates through TriLink and Cygnus, with customer-facing brands including TriLink BioTechnologies, Glen Research, Cygnus Technologies, and Alphazyme. TriLink covers RNA synthesis, mRNA production, CleanCap capping technology, oligonucleotide reagents, enzymes, and CDMO services; Cygnus covers biologics safety testing, impurity analytics, and viral-clearance products.
Serves global biopharma, emerging biotech, diagnostics, and research customers from a revenue base concentrated in North America, with additional sales in Asia Pacific and EMEA. The portfolio fits regulated drug-development workflows where reagent quality, assay specificity, and manufacturing support matter.
Demand depends on nucleic-acid therapy activity, biologics manufacturing pipelines, and uneven CleanCap orders tied to commercial vaccine programs. Recent operations also reflect a cost-structure reset under new leadership.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 9, 2026 | UBS | Initiate | Rating: —Target: — | Target: $8 |
| May 8, 2026 | Deutsche Bank | Target | Target: $25 | Target: $6 |
| Dec 15, 2025 | Wells Fargo | Reiterate | Rating: —Target: — | Target: $4.50 |
| Feb 26, 2025 | Baird | Downgrade | ||
| Dec 5, 2024 | Goldman Sachs | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $70.1M · Total debt $176.7M · Total assets $603.7M · Shareholders' equity $204.6M
- Revenue
- $51.4M
- Operating income
- −$15.1M
- Net income
- −$12.4M
No dividends on record.
| Institutions | ≈ 54.18% | 140.70M shares | |
|---|---|---|---|
| 187 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 2.46% | 6.39M shares | |
| 19 holders · as of Sep 9, 2026 | |||
| Strategic holders | 72.64% | 188.62M shares | |
| 1 holder · as of Feb 11, 2021 | |||
| Adds to | 129.28% | ||
259.67M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (259.67M in the company's Sep 22, 2026 report, 145.10M elsewhere); stakes use the report.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 129.28%; nothing is left for Other.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
GTCR Investment Xi LLC1,2Strategicdirector, 10 percent owner | 72.64% | 110.68M B · 110.68M | filed Feb 11, 2021 |
GTCR LLCInstitution | 7.76% | 20.15M A | as of Jun 30, 2026 |
Massachusetts Financial Services Company ("MFS")Institution | 5.37% | 13.93M | filed Sep 6, 2022 |
BlackRock, Inc.Institution | 3.84% | 9.97M A | as of Jun 30, 2026 |
Braidwell LPInstitution | 3.35% | 8.70M A | as of Jun 30, 2026 |
- GTCR Investment Xi LLC reports a block also reported by GTCR LLC; it is counted once, under GTCR LLC.
- The filed share classes (B, COMMON) could not be matched to the company's, so no percentage.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 10, 2026 | Kurt Oreshack | officer: General Counsel | −25,000 | $5.10 |
| Jun 9, 2026 | Kurt Oreshack | officer: General Counsel | −25,000 | $5.06 |
| Dec 5, 2025 | Gregory T. Lucier | director | +51,472 | $3.70 |
| Dec 8, 2025 | Gregory T. Lucier | director | +48,528 | $3.67 |
| Nov 13, 2025 | Bernd Brust | director, officer: Chief Executive Officer | +216,212 | $3.25 |
- Danaher
Broad genomic-medicine scale rival through Aldevron and IDT
- Thermo Fisher Scientific
Large life-science tools rival in mRNA, oligos, and enzymes
- Agilent Technologies
Therapeutic oligo CDMO rival with expanding nucleic-acid capacity
- Bio-Rad Laboratories
Bioprocess assay and HCP workflow rival for Cygnus
- Twist Bioscience
Synthetic DNA and long-oligo scale rival
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Maravai LifeSciences | $7.45 | 0.00% | $1.98B | — | — | 9.5 | +8.5% |
| Danaher | $220.87 | −0.11% | $151.67B | 38.3 | 25.0 | 6.0 | +5.5% |
| Thermo Fisher Scientific | $658.52 | −0.03% | $244.81B | 35.4 | 25.1 | 5.3 | +10.5% |
| Agilent Technologies | $167.26 | −0.02% | $45.75B | 31.9 | 25.5 | 6.2 | +8.1% |
| Bio-Rad Laboratories | $379.57 | −0.01% | $10.16B | 45.7 | 36.8 | 3.9 | −0.1% |
| Twist Bioscience | $164.60 | +0.04% | $10.33B | — | — | 23.9 | +23.3% |
| Median | 36.9 | 25.3 | 6.0 | +8.1% |